- Home
- AEF vs SGHT Comparison
AEF vs SGHT Comparison
Compare AEF & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEF
- SGHT
- Stock Information
- Founded
- AEF 1989
- SGHT 2011
- Country
- AEF United States
- SGHT United States
- Employees
- AEF N/A
- SGHT N/A
- Industry
- AEF Finance/Investors Services
- SGHT Medical Specialities
- Sector
- AEF Finance
- SGHT Health Care
- Exchange
- AEF Nasdaq
- SGHT Nasdaq
- Market Cap
- AEF 196.1M
- SGHT 217.7M
- IPO Year
- AEF N/A
- SGHT 2021
- Fundamental
- Price
- AEF $5.94
- SGHT $4.22
- Analyst Decision
- AEF
- SGHT Buy
- Analyst Count
- AEF 0
- SGHT 8
- Target Price
- AEF N/A
- SGHT $4.01
- AVG Volume (30 Days)
- AEF 92.5K
- SGHT 176.9K
- Earning Date
- AEF 01-01-0001
- SGHT 07-31-2025
- Dividend Yield
- AEF 7.13%
- SGHT N/A
- EPS Growth
- AEF N/A
- SGHT N/A
- EPS
- AEF 0.57
- SGHT N/A
- Revenue
- AEF N/A
- SGHT $78,109,000.00
- Revenue This Year
- AEF N/A
- SGHT N/A
- Revenue Next Year
- AEF N/A
- SGHT $11.60
- P/E Ratio
- AEF $8.86
- SGHT N/A
- Revenue Growth
- AEF N/A
- SGHT N/A
- 52 Week Low
- AEF $4.40
- SGHT $2.03
- 52 Week High
- AEF $5.53
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- AEF 67.14
- SGHT 61.79
- Support Level
- AEF $5.51
- SGHT $4.02
- Resistance Level
- AEF $5.77
- SGHT $4.46
- Average True Range (ATR)
- AEF 0.08
- SGHT 0.22
- MACD
- AEF 0.00
- SGHT -0.03
- Stochastic Oscillator
- AEF 95.00
- SGHT 71.43
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.